Skip to main content
Top
Published in: BMC Medical Imaging 1/2014

Open Access 01-12-2014 | Research article

Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness

Authors: Andrei Lebovici, Silviu A Sfrangeu, Diana Feier, Cosmin Caraiani, Ciprian Lucan, Mihai Suciu, Florin Elec, Gheorghita Iacob, Mircea Buruian

Published in: BMC Medical Imaging | Issue 1/2014

Login to get access

Abstract

Background

We tested the feasibility of a simple method for assessment of prostate cancer (PCa) aggressiveness using diffusion-weighted magnetic resonance imaging (MRI) to calculate apparent diffusion coefficient (ADC) ratios between prostate cancer and healthy prostatic tissue.

Methods

The requirement for institutional review board approval was waived. A set of 20 standardized core transperineal saturation biopsy specimens served as the reference standard for placement of regions of interest on ADC maps in tumorous and normal prostatic tissue of 22 men with PCa (median Gleason score: 7; range, 6–9). A total of 128 positive sectors were included for evaluation. Two diagnostic ratios were computed between tumor ADCs and normal sector ADCs: the ADC peripheral ratio (the ratio between tumor ADC and normal peripheral zone tissue, ADC-PR), and the ADC central ratio (the ratio between tumor ADC and normal central zone tissue, ADC-CR). The performance of the two ratios in detecting high-risk tumor foci (Gleason 8 and 9) was assessed using the area under the receiver operating characteristic curve (AUC).

Results

Both ADC ratios presented significantly lower values in high-risk tumors (0.48 ± 0.13 for ADC-CR and 0.40 ± 0.09 for ADC-PR) compared with low-risk tumors (0.66 ± 0.17 for ADC-CR and 0.54 ± 0.09 for ADC-PR) (p < 0.001) and had better diagnostic performance (ADC-CR AUC = 0.77, sensitivity = 82.2%, specificity = 66.7% and ADC-PR AUC = 0.90, sensitivity = 93.7%, specificity = 80%) than stand-alone tumor ADCs (AUC of 0.75, sensitivity = 72.7%, specificity = 70.6%) for identifying high-risk lesions.

Conclusions

The ADC ratio as an intrapatient-normalized diagnostic tool may be better in detecting high-grade lesions compared with analysis based on tumor ADCs alone, and may reduce the rate of biopsies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Melnikow J, LeFevre M, Wilt TJ, Moyer VA: Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care. 2013, 51: 301-303.PubMed Melnikow J, LeFevre M, Wilt TJ, Moyer VA: Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care. 2013, 51: 301-303.PubMed
2.
go back to reference Bozzini G, Colin P, Nevoux P, Villers A, Mordon S, Betrouni N: Focal therapy of prostate cancer: energies and procedures. Urol Oncol. 2013, 31: 155-167. 10.1016/j.urolonc.2012.05.011.CrossRefPubMed Bozzini G, Colin P, Nevoux P, Villers A, Mordon S, Betrouni N: Focal therapy of prostate cancer: energies and procedures. Urol Oncol. 2013, 31: 155-167. 10.1016/j.urolonc.2012.05.011.CrossRefPubMed
3.
go back to reference Scardino PT, Weaver R, Hudson MA: Early detection of prostate cancer. Hum Pathol. 1992, 23: 211-222. 10.1016/0046-8177(92)90102-9.CrossRefPubMed Scardino PT, Weaver R, Hudson MA: Early detection of prostate cancer. Hum Pathol. 1992, 23: 211-222. 10.1016/0046-8177(92)90102-9.CrossRefPubMed
4.
go back to reference Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, Roobol MJ: Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol. 2008, 53: 468-477. 10.1016/j.eururo.2007.10.047.CrossRefPubMed Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, Roobol MJ: Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol. 2008, 53: 468-477. 10.1016/j.eururo.2007.10.047.CrossRefPubMed
5.
go back to reference Gómez Veiga F, Ponce Reixa J, Barbagelata López A, Fernández Rosado E, Gonzaĺez MM: Current role of PSA and other markers in the diagnosis of prostate cancer. Arch Esp Urol. 2006, 59: 1069-1082.CrossRefPubMed Gómez Veiga F, Ponce Reixa J, Barbagelata López A, Fernández Rosado E, Gonzaĺez MM: Current role of PSA and other markers in the diagnosis of prostate cancer. Arch Esp Urol. 2006, 59: 1069-1082.CrossRefPubMed
6.
go back to reference Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ: Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics. 2011, 31: 677-703. 10.1148/rg.313105139.CrossRefPubMedPubMedCentral Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ: Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics. 2011, 31: 677-703. 10.1148/rg.313105139.CrossRefPubMedPubMedCentral
7.
go back to reference Verma S, Rajesh A, Morales H, Lemen L, Bills G, Delworth M, Gaitonde K, Ying J, Samartunga R, Lamba M: Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. Am J Roentgenol. 2011, 196: 374-381. 10.2214/AJR.10.4441.CrossRef Verma S, Rajesh A, Morales H, Lemen L, Bills G, Delworth M, Gaitonde K, Ying J, Samartunga R, Lamba M: Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. Am J Roentgenol. 2011, 196: 374-381. 10.2214/AJR.10.4441.CrossRef
8.
go back to reference Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974, 111: 58-64.PubMed Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974, 111: 58-64.PubMed
9.
go back to reference Bianco FJ, Wood DP, Cher ML, Powell IJ, Souza JW, Pontes JE: Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer. 2003, 1: 242-247. 10.3816/CGC.2003.n.006.CrossRefPubMed Bianco FJ, Wood DP, Cher ML, Powell IJ, Souza JW, Pontes JE: Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer. 2003, 1: 242-247. 10.3816/CGC.2003.n.006.CrossRefPubMed
10.
go back to reference Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ, European Society of Urogenital Radiology: ESUR prostate MR guidelines 2012. Eur Radiol. 2012, 22 (4): 746-757. 10.1007/s00330-011-2377-y.CrossRefPubMedPubMedCentral Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ, European Society of Urogenital Radiology: ESUR prostate MR guidelines 2012. Eur Radiol. 2012, 22 (4): 746-757. 10.1007/s00330-011-2377-y.CrossRefPubMedPubMedCentral
11.
go back to reference Aigner F, Pallwein L, Pelzer A, Schaefer G, Bartsch G, Nedden D, Frauscher F: Value of magnetic resonance imaging in prostate cancer diagnosis. World J Urol. 2007, 25: 351-359. 10.1007/s00345-007-0187-2.CrossRefPubMed Aigner F, Pallwein L, Pelzer A, Schaefer G, Bartsch G, Nedden D, Frauscher F: Value of magnetic resonance imaging in prostate cancer diagnosis. World J Urol. 2007, 25: 351-359. 10.1007/s00345-007-0187-2.CrossRefPubMed
12.
go back to reference Chen YJ, Chu WC, Pu YS, Chueh SC, Shun CT, Tseng WY: Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer. J Magn Reson Imaging. 2012, 36: 912-919. 10.1002/jmri.23723.CrossRefPubMed Chen YJ, Chu WC, Pu YS, Chueh SC, Shun CT, Tseng WY: Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer. J Magn Reson Imaging. 2012, 36: 912-919. 10.1002/jmri.23723.CrossRefPubMed
13.
go back to reference Boonsirikamchai P, Choi S, Frank SJ, Ma J, Elsayes KM, Kaur H, Choi H: MR Imaging of Prostate Cancer in Radiation Oncology: What Radiologists Need to Know. Radiographics. 2013, 33: 741-761. 10.1148/rg.333125041.CrossRefPubMed Boonsirikamchai P, Choi S, Frank SJ, Ma J, Elsayes KM, Kaur H, Choi H: MR Imaging of Prostate Cancer in Radiation Oncology: What Radiologists Need to Know. Radiographics. 2013, 33: 741-761. 10.1148/rg.333125041.CrossRefPubMed
14.
go back to reference Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF: Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roentgenol. 2010, 194: W316-W322. 10.2214/AJR.09.2651.CrossRef Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF: Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roentgenol. 2010, 194: W316-W322. 10.2214/AJR.09.2651.CrossRef
15.
go back to reference Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M: Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011, 59 (4): 477-494. 10.1016/j.eururo.2010.12.009.CrossRefPubMed Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M: Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011, 59 (4): 477-494. 10.1016/j.eururo.2010.12.009.CrossRefPubMed
16.
go back to reference Litjens GJ, Hambrock T, Hulsbergen–van de Kaa C, Barentsz JO: Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness. Radiology. 2012, 265: 260-266. 10.1148/radiol.12112374.CrossRefPubMed Litjens GJ, Hambrock T, Hulsbergen–van de Kaa C, Barentsz JO: Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness. Radiology. 2012, 265: 260-266. 10.1148/radiol.12112374.CrossRefPubMed
17.
go back to reference Hosseinzadeh K, Schwarz SD: Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004, 20: 654-661. 10.1002/jmri.20159.CrossRefPubMed Hosseinzadeh K, Schwarz SD: Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004, 20: 654-661. 10.1002/jmri.20159.CrossRefPubMed
18.
go back to reference Yamamura J, Salomon G, Buchert R, Hohenstein A, Graessner J, Huland H, Graefen M, Adam G, Wedegaertner U: Magnetic resonance imaging of prostate cancer: diffusion-weighted imaging in comparison with sextant biopsy. J Comput Assist Tomogr. 2011, 35: 223-228. 10.1097/RCT.0b013e3181fc5409.CrossRefPubMed Yamamura J, Salomon G, Buchert R, Hohenstein A, Graessner J, Huland H, Graefen M, Adam G, Wedegaertner U: Magnetic resonance imaging of prostate cancer: diffusion-weighted imaging in comparison with sextant biopsy. J Comput Assist Tomogr. 2011, 35: 223-228. 10.1097/RCT.0b013e3181fc5409.CrossRefPubMed
19.
go back to reference Rinaldi D, Fiocchi F, Ligabue G, Bianchi G, Torricelli P: Role of diffusion-weighted magnetic resonance imaging in prostate cancer evaluation. Radiol Med. 2012, 117: 1429-1440. 10.1007/s11547-012-0832-8.CrossRefPubMed Rinaldi D, Fiocchi F, Ligabue G, Bianchi G, Torricelli P: Role of diffusion-weighted magnetic resonance imaging in prostate cancer evaluation. Radiol Med. 2012, 117: 1429-1440. 10.1007/s11547-012-0832-8.CrossRefPubMed
20.
go back to reference Nagayama M, Watanabe Y, Terai A, Araki T, Notohara K, Okumura A, Amoh Y, Ishimori T, Nakashita S, Dodo Y: Determination of the cutoff level of apparent diffusion coefficient values for detection of prostate cancer. Jpn J Radiol. 2011, 29 (7): 488-494. 10.1007/s11604-011-0586-6.CrossRefPubMed Nagayama M, Watanabe Y, Terai A, Araki T, Notohara K, Okumura A, Amoh Y, Ishimori T, Nakashita S, Dodo Y: Determination of the cutoff level of apparent diffusion coefficient values for detection of prostate cancer. Jpn J Radiol. 2011, 29 (7): 488-494. 10.1007/s11604-011-0586-6.CrossRefPubMed
21.
go back to reference Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T, Dahi F, Shalhav AL, Karczmar G, Stadler WM: Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2010, 257 (3): 715-723. 10.1148/radiol.10100021.CrossRefPubMed Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T, Dahi F, Shalhav AL, Karczmar G, Stadler WM: Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2010, 257 (3): 715-723. 10.1148/radiol.10100021.CrossRefPubMed
22.
go back to reference Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, van Oort IM, van Basten JP, Karthaus HF, Witjes JA, Barentsz JO: Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol. 2012, 47: 153-158.PubMed Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, van Oort IM, van Basten JP, Karthaus HF, Witjes JA, Barentsz JO: Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol. 2012, 47: 153-158.PubMed
23.
go back to reference Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol. 2001, 166 (5): 1679-1683. 10.1016/S0022-5347(05)65652-2.CrossRefPubMed Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol. 2001, 166 (5): 1679-1683. 10.1016/S0022-5347(05)65652-2.CrossRefPubMed
24.
go back to reference Cookson MS, Fleshner NE, Soloway SM, Fair WR: Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997, 157 (2): 559-562. 10.1016/S0022-5347(01)65201-7.CrossRefPubMed Cookson MS, Fleshner NE, Soloway SM, Fair WR: Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997, 157 (2): 559-562. 10.1016/S0022-5347(01)65201-7.CrossRefPubMed
25.
go back to reference Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA: Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013, 189 (1 Suppl): S12-S17. discussion S17-18CrossRefPubMed Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA: Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013, 189 (1 Suppl): S12-S17. discussion S17-18CrossRefPubMed
Metadata
Title
Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness
Authors
Andrei Lebovici
Silviu A Sfrangeu
Diana Feier
Cosmin Caraiani
Ciprian Lucan
Mihai Suciu
Florin Elec
Gheorghita Iacob
Mircea Buruian
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Medical Imaging / Issue 1/2014
Electronic ISSN: 1471-2342
DOI
https://doi.org/10.1186/1471-2342-14-15

Other articles of this Issue 1/2014

BMC Medical Imaging 1/2014 Go to the issue